Table 1. Patient Characteristics.
| Clinical Characteristic | Prostate Cancer Negative (n = 365) | Prostate Cancer Positive (n = 655)a | P Value | Total (N = 1020) |
|---|---|---|---|---|
| Age, median (IQR), y | 64 (59-69) | 68 (62-72) | <.001 | 67 (61-71) |
| PSA, median (IQR), ng/mL | 6.4 (5.2-8.9) | 9.2 (6.1-19.9) | .03 | 8.0 (5.7-13.0) |
| Prostate volume, median (IQR), cm3 | 65 (49-88) | 47 (36-61) | <.001 | 53 (40-72) |
| PSA density, median (IQR), ng/mL/cm3 | 0.10 (0.07-0.14) | 0.20 (0.12-0.43) | <.001 | 0.15 (0.10-0.27) |
| Time from bpMRI to biopsy, median (IQR), d | 7 (4-11) | 7 (5-9) | .44 | 7 (7-9) |
| cTDRE stage, No. (%) | ||||
| Nonpalpable tumor | <.001b | |||
| Tx | 106 (29) | 69 (11) | 175 (17) | |
| T1c | 208 (57) | 260 (40) | 468 (46) | |
| Palpable tumor | ||||
| T2 | 46 (13) | 199 (30) | 245 (24) | |
| T3 | 5 (1) | 120 (18) | 125 (12) | |
| T4 | 0 | 7 (1) | 7 (1) |
Abbreviations: bpMRI, biparametric magnetic resonance imaging; cTDRE, tumor stage determined by digital rectal examination; IQR, interquartile range; PSA, prostate-specific antigen.
SI conversion factor: To convert PSA to micrograms per liter, multiply by 1.0.
a
Based on biopsy results of combined biopsies in all men.
b
A Fisher exact test was used to compare the cTDRE stage pooled in nonpalpable and palpable tumor groups.